Insulet Co. (NASDAQ:PODD) Receives $253.27 Average Target Price from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have earned an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $253.27.

A number of brokerages have recently weighed in on PODD. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Piper Sandler lifted their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Citigroup lifted their price target on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Canaccord Genuity Group lifted their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, BTIG Research lifted their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

Insulet Price Performance

Shares of PODD opened at $266.42 on Friday. Insulet has a twelve month low of $160.19 and a twelve month high of $279.40. The firm’s fifty day simple moving average is $241.97 and its 200-day simple moving average is $211.65. The firm has a market capitalization of $18.69 billion, a price-to-earnings ratio of 45.62, a PEG ratio of 4.02 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Insulet in the second quarter valued at about $32,000. Venturi Wealth Management LLC boosted its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Finally, CVA Family Office LLC boosted its holdings in shares of Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.